These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

186 related items for PubMed ID: 32219919

  • 1. Treatment change and coronary artery abnormality in incomplete Kawasaki disease.
    Nomura Y, Yashiro M, Masuda K, Nakamura Y.
    Pediatr Int; 2020 Jul; 62(7):779-784. PubMed ID: 32219919
    [Abstract] [Full Text] [Related]

  • 2. Correlation of Coronary Artery Abnormalities with Fever Pattern in Patients with Kawasaki Disease.
    Tanaka A, Inoue M, Hoshina T, Koga H.
    J Pediatr; 2021 Sep; 236():95-100. PubMed ID: 34019881
    [Abstract] [Full Text] [Related]

  • 3. A Retrospective Cohort Study of Intravenous Immunoglobulin Therapy in the Acute Phase of Kawasaki Disease: The Earlier, the Better?
    Li W, He X, Zhang L, Wang Z, Wang Y, Lin H, Yuan J, Xie X, Qin Y, Huang P.
    Cardiovasc Ther; 2021 Sep; 2021():6660407. PubMed ID: 34239607
    [Abstract] [Full Text] [Related]

  • 4. Platelet Count Variation and Risk for Coronary Artery Abnormalities in Kawasaki Disease.
    Ae R, Abrams JY, Maddox RA, Schonberger LB, Nakamura Y, Shindo A, Kuwabara M, Makino N, Matsubara Y, Kosami K, Sasahara T, Belay ED.
    Pediatr Infect Dis J; 2020 Mar; 39(3):197-203. PubMed ID: 31851145
    [Abstract] [Full Text] [Related]

  • 5. Kawasaki disease in Turkish children: a single center experience with emphasis on intravenous immunoglobulin resistance and giant coronary aneurysms.
    Yılmazer MM, Özdemir R, Meşe T, Küçük M, Öner T, Devrim İ, Bayram N, Güven B, Tavlı V.
    Turk J Pediatr; 2019 Mar; 61(5):648-656. PubMed ID: 32104995
    [Abstract] [Full Text] [Related]

  • 6. Predictors for intravenous immunoglobulin resistance and coronary artery lesions in Kawasaki disease.
    Xie T, Wang Y, Fu S, Wang W, Xie C, Zhang Y, Gong F.
    Pediatr Rheumatol Online J; 2017 Mar 21; 15(1):17. PubMed ID: 28320400
    [Abstract] [Full Text] [Related]

  • 7. Epidemiological and Clinical Characteristics of Kawasaki Disease and Factors Associated with Coronary Artery Abnormalities in East China: Nine Years Experience.
    Tang Y, Gao X, Shen J, Sun L, Yan W.
    J Trop Pediatr; 2016 Apr 21; 62(2):86-93. PubMed ID: 26884440
    [Abstract] [Full Text] [Related]

  • 8. Low risk of treatment resistance in Down syndrome with Kawasaki disease.
    Takatsuki S, Ogata S, Ishii M, Yokozawa M, Ono M, Fujiwara M, Ida H, Motomura H, Moriuchi H, Taketazu M, Kawamura Y, Kawano T, Izumi T, Shiono J, Tsuchiya S, Tsuchiya K, Goushi T, Ichida F, Saji T.
    Pediatr Int; 2017 Dec 21; 59(12):1236-1239. PubMed ID: 28960680
    [Abstract] [Full Text] [Related]

  • 9. The effects of early intravenous immunoglobulin therapy for Kawasaki disease: The 22nd nationwide survey in Japan.
    Kuwabara M, Yashiro M, Ae R, Yanagawa H, Nakamura Y.
    Int J Cardiol; 2018 Oct 15; 269():334-338. PubMed ID: 30049499
    [Abstract] [Full Text] [Related]

  • 10. Epidemiologic Features of Kawasaki Disease in Shanghai From 2013 Through 2017.
    Xie LP, Yan WL, Huang M, Huang MR, Chen S, Huang GY, Liu F.
    J Epidemiol; 2020 Oct 05; 30(10):429-435. PubMed ID: 31548437
    [Abstract] [Full Text] [Related]

  • 11. Prevalence of coronary artery abnormality in incomplete Kawasaki disease.
    Sonobe T, Kiyosawa N, Tsuchiya K, Aso S, Imada Y, Imai Y, Yashiro M, Nakamura Y, Yanagawa H.
    Pediatr Int; 2007 Aug 05; 49(4):421-6. PubMed ID: 17587261
    [Abstract] [Full Text] [Related]

  • 12. Treatment of acute Kawasaki disease: aspirin's role in the febrile stage revisited.
    Hsieh KS, Weng KP, Lin CC, Huang TC, Lee CL, Huang SM.
    Pediatrics; 2004 Dec 05; 114(6):e689-93. PubMed ID: 15545617
    [Abstract] [Full Text] [Related]

  • 13. Analysis of Age, Sex, Lack of Response to Intravenous Immunoglobulin, and Development of Coronary Artery Abnormalities in Children With Kawasaki Disease in Japan.
    Takekoshi N, Kitano N, Takeuchi T, Suenaga T, Kakimoto N, Suzuki T, Kada TT, Shibuta S, Tachibana S, Murayama Y, Yamaga H, Suzuki H.
    JAMA Netw Open; 2022 Jun 01; 5(6):e2216642. PubMed ID: 35696166
    [Abstract] [Full Text] [Related]

  • 14. Efficacy of primary treatment with immunoglobulin plus ciclosporin for prevention of coronary artery abnormalities in patients with Kawasaki disease predicted to be at increased risk of non-response to intravenous immunoglobulin (KAICA): a randomised controlled, open-label, blinded-endpoints, phase 3 trial.
    Hamada H, Suzuki H, Onouchi Y, Ebata R, Terai M, Fuse S, Okajima Y, Kurotobi S, Hirai K, Soga T, Ishiguchi Y, Okuma Y, Takada N, Yanai M, Sato J, Nakayashiro M, Ayusawa M, Yamamoto E, Nomura Y, Hashimura Y, Ouchi K, Masuda H, Takatsuki S, Hirono K, Ariga T, Higaki T, Otsuki A, Terauchi M, Aoyagi R, Sato T, Fujii Y, Fujiwara T, Hanaoka H, Hata A, KAICA trial Investigators.
    Lancet; 2019 Mar 16; 393(10176):1128-1137. PubMed ID: 30853151
    [Abstract] [Full Text] [Related]

  • 15. Clinically useful predictors of resistance to intravenous immunoglobulin and prognosis of coronary artery lesions in patients with incomplete kawasaki disease.
    Cho KH, Kang SJ.
    Korean Circ J; 2014 Sep 16; 44(5):328-35. PubMed ID: 25278986
    [Abstract] [Full Text] [Related]

  • 16. Clinical manifestations and risk factors of coronary artery lesions in children with Kawasaki disease.
    Wang L, Zeng X, Chen B.
    Medicine (Baltimore); 2023 Sep 15; 102(37):e34939. PubMed ID: 37713854
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and safety of intravenous immunoglobulin plus prednisolone therapy in patients with Kawasaki disease (Post RAISE): a multicentre, prospective cohort study.
    Miyata K, Kaneko T, Morikawa Y, Sakakibara H, Matsushima T, Misawa M, Takahashi T, Nakazawa M, Tamame T, Tsuchihashi T, Yamashita Y, Obonai T, Chiga M, Hori N, Komiyama O, Yamagishi H, Miura M, Post RAISE group.
    Lancet Child Adolesc Health; 2018 Dec 15; 2(12):855-862. PubMed ID: 30337183
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and safety associated with the infusion speed of intravenous immunoglobulin for the treatment of Kawasaki disease: a randomized controlled trial.
    Fukui S, Seki M, Minami T, Kotani K, Oka K, Yokomizo A, Matsubara D, Sato T, Nozaki Y, Saito M, Kikuchi Y, Miyamoto K, Monden Y, Yamagata T.
    Pediatr Rheumatol Online J; 2021 Jul 03; 19(1):107. PubMed ID: 34217297
    [Abstract] [Full Text] [Related]

  • 19. Timing of intravenous immunoglobulin treatment and risk of coronary artery abnormalities in children with Kawasaki disease.
    Bal AK, Prasad D, Umali Pamintuan MA, Mammen-Prasad E, Petrova A.
    Pediatr Neonatol; 2014 Oct 03; 55(5):387-92. PubMed ID: 24636168
    [Abstract] [Full Text] [Related]

  • 20. The time option of IVIG treatment is associated with therapeutic responsiveness and coronary artery abnormalities but not with clinical classification in the acute episode of Kawasaki disease.
    Samadli S, Liu FF, Mammadov G, Wang JJ, Liu HH, Wu YF, Luo HH, Wu Y, Chen WX, Zhang DD, Wei W, Hu P.
    Pediatr Rheumatol Online J; 2019 Jul 31; 17(1):53. PubMed ID: 31366406
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.